Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Research

• Publication date

  2000-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11016643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture

  2004cited by this paper
• Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells

  2004cited by this paper
• Anthracycline-induced cardiotoxicity.

  2000cited by this paper
• Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice.

  1999cited by this paper
• Inhibition of Aldo‐keto Reductases by Phenobarbital Alters Metabolism, Pharmacokinetics and Toxicity of Doxorubicin in Rats

  1999cited by this paper
• Redox regulation of signal transduction in cardiac and smooth muscle.

  1999cited by this paper
• A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

  1999cited by this paper
• A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.

  1999cited by this paper
• The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardium

  1998cited by this paper
• Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy

  1997cited by this paper
• Isolation of high molecular weight DNA for reliable genotyping of transgenic mice.

  1997cited by this paper
• Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity.

  1997cited by this paper
• Antigen retrieval techniques in immunohistochemistry: comparison of different methods

  1997cited by this paper
• Cytoprotective agents for anthracyclines.

  1996cited by this paper
• Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice A new model to test potential protectors

  1996cited by this paper
• Anthracycline-Induced Cardiotoxicity

  1996cited by this paper
• The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice.

  1996cited by this paper
• Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.

  1995cited by this paper
• Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast.

  1994cited by this paper
• Time‐related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function

  1993cited by this paper
• Isolation and characterization of the mouse cardiac myosin heavy chain genes.

  1991cited by this paper
• Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.

  1991cited by this paper
• Actin isoform mRNA alterations induced by doxorubicin in cultured heart cells.

  1990cited by this paper
• Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.

  1990cited by this paper
• Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

  1990cited by this paper
• Induction of a human carbonyl reductase gene located on chromosome 21.

  1990cited by this paper
• Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity.

  1988cited by this paper
• Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

  1988cited by this paper
• The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.

  1987cited by this paper
• Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat.

  1986cited by this paper
• Carbonyl reductase provides the enzymatic basis of quinone detoxication in man.

  1986cited by this paper
• General and cardiac toxicity of adriamycinol in rats.

  1986cited by this paper
• Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells.

  1986cited by this paper
• Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase.

  1986cited by this paper
• Loop-column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma.

  1985cited by this paper
• Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum.

  1985cited by this paper
• Might adriamycinol contribute to adriamycin-induced cardiotoxicity?

  1985cited by this paper
• Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines.

  1985cited by this paper
• Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.

  1983cited by this paper
• Effect of anthracycline antibiotics on oxygen radical formation in rat heart.

  1983cited by this paper
• Daunorubicin reduction mediated by aldehyde and ketone reductases.

  1981cited by this paper
• Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.

  1981cited by this paper
• Mammalian carbonyl reductases.

  1980influential reference
• Purification and Properties of an NADPH-dependent Carbonyl Reductase from Human Brain

  1980cited by this paper
• Isolation and characterization of rabbit liver xenobiotic carbonyl reductases.

  1980cited by this paper
• Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.

  1980cited by this paper
• Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers.

  1978cited by this paper
• Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.

  1977cited by this paper
• Cellular pharmocodynamics of several anthrocycline antibiotics.

  1976cited by this paper
• Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes.

  1976cited by this paper
• DAUNORUBICINOL, A MAJOR METABOLITE OF DAUNORTJBICIN: ISOLATION FROM HUMAN URINE AND ENZYMATIC REACTIONS

  1971cited by this paper
• Daunorubicin metabolism by rat tissue preparations.

  1971cited by this paper

• Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies

  2025cites this paper
• Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients

  2025cites this paper
• Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection

  2025cites this paper
• Comparative In Vitro Study of the Cytotoxic Effects of Doxorubicin’s Main Metabolites on Cardiac AC16 Cells Versus the Parent Drug

  2024cites this paper
• Carbonyl reductase 1: a novel regulator of blood pressure in Down syndrome

  2024cites this paper
• Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients

  2024cites this paper
• In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics

  2023cites this paper
• Inhibition of human carbonyl reducing enzymes by plant anthrone and anthraquinone derivatives.

  2022cites this paper
• Development of transgenic mice overexpressing mouse carbonyl reductase 1

  2022cites this paper
• Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver

  2022cites this paper
• Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis

  2022cites this paper
• Preparation, Properties and Crystal Structure of syn-Isomer of 2,6-Dichlorophenyl-cyanoxime, H(2,6-diCl-PhCO): Potent Carbonyl Reductase Inhibitor

  2021cites this paper
• Pediatric Chemotherapy Drugs Associated With Cardiotoxicity

  2021cites this paper
• Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies

  2021cites this paper
• Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.

  2021cites this paper
• Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified

  2020cites this paper
• Overview on the Side Effects of Doxorubicin

  2020cites this paper
• Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - involvement of carbonyl reductase 1.

  2020cites this paper
• Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report

  2020cites this paper
• The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

  2019cites this paper
• Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature.

  2019cites this paper
• Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling

  2019cites this paper
• Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin.

  2019cites this paper
• 11β-Hydroxysteroid Dehydrogenase 1 Human Tissue Distribution, Selective Inhibitor, and Role in Doxorubicin Metabolism

  2018cites this paper
• Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview

  2017cites this paper
• Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment

  2017cites this paper
• Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents

  2017cites this paper
• Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults

  2017cites this paper
• Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

  2017cites this paper
• The role of carbonyl reductase 1 in drug discovery and development

  2017cites this paper
• Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review

  2016cites this paper
• Mitoxantrone, More than Just Another Topoisomerase II Poison

  2016cites this paper
• Risk factors for anthracycline-associated cardiotoxicity

  2016cites this paper
• Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.

  2016cites this paper
• Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors

  2016cites this paper
• Implications of Kidney Disease on Metabolic Reduction.

  2016cites this paper
• Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.

  2016cites this paper
• Medición y monitorización del daño cardiaco por antraciclinas Measurement and monitorization of cardiac damage with anthracyclines

  2016cites this paper
• Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

  2015cites this paper
• Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.

  2015cites this paper
• Structure-activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1).

  2015cites this paper
• Protective effect of 23‐hydroxybetulinic acid on doxorubicin‐induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase‐mediated metabolism

  2015cites this paper
• The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.

  2015cites this paper
• Near infra-red laser mediated photothermal and antitumor efficacy of doxorubicin conjugated gold nanorods with reduced cardiotoxicity in swiss albino mice.

  2015cites this paper
• Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.

  2015cites this paper
• Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218

  2015cites this paper
• CHARACTERIZATION OF THE EFFECT OF CHRONIC KIDNEY DISEASE ON HEPATIC DRUG REDUCTION: IN-VITRO AND IN-VIVO STUDIES OF WARFARIN

  2014cites this paper
• The Synthesis and in Vitro Toxicological Evaluation of the Mitoxantrone Naphthoquinoxaline Metabolite: A Comparative Study with the Parent Drug

  2014influential citation
• Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group

  2014cites this paper
• Ranolazine in the prevention of anthracycline cardiotoxicity.

  2014cites this paper
• What is cardiotoxicity

  2014cites this paper
• Animal Models in Studies of Cardiotoxicity Side Effects from Antiblastic Drugs in Patients and Occupational Exposed Workers

  2014cites this paper
• Metabolism (Non-CYP Enzymes)

  2014cites this paper
• Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A

  2014cites this paper
• A Correlation between Cytotoxicity and Reductase-Mediated Metabolism in Cell Lines Treated with Doxorubicin and Daunorubicin

  2013cites this paper
• Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2.

  2013cites this paper
• Microsoft Word-27383625-file00.docx

  2013cites this paper
• Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function

  2013cites this paper
• Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase

  2013cites this paper
• changes in iron metabolism induced by doxorubicin Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates

  2013cites this paper
• The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress.

  2013cites this paper
• Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

  2013cites this paper
• DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.

  2012cites this paper
• Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/− mice

  2012cites this paper
• MicroRNAs Differentially Regulate Carbonyl Reductase 1 (CBR1) Gene Expression Dependent on the Allele Status of the Common Polymorphic Variant rs9024

  2012cites this paper
• Anthracyclines and mitochondria.

  2012cites this paper
• Doxorubicin-induced cardiotoxicity in mice; protection by silymarin

  2012cites this paper
• Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

  2012cites this paper
• Unexpected doxorubicin-induced cardiomyopathy in sisters

  2012cites this paper
• Amrubicin, a Completely Synthetic 9‐Aminoanthracycline for Extensive‐Disease Small‐Cell Lung Cancer

  2012cites this paper
• Anthracycline cardiotoxicity

  2012cites this paper
• A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.

  2012cites this paper
• The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms

  2012cites this paper
• Single-Nucleotide Polymorphisms in Aldo-Keto and Carbonyl Reductase Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy

  2012cites this paper
• Pharmacogenomics of serious adverse drug reactions in pediatric oncology.

  2011cites this paper
• Effect of exercise on cardiac function and doxorubicin accumulation in left ventricular tissue of rats

  2011cites this paper
• Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase.

  2011cites this paper
• Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors

  2011cites this paper
• Functional characterization of drug uptake and metabolism in the heart

  2011cites this paper
• Carbonyl reductase 1 as a novel target of (−)‐epigallocatechin gallate against hepatocellular carcinoma

  2010cites this paper
• Expression of the Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 in Hearts from Donors with Down Syndrome

  2010cites this paper
• NADPH-dependent Reductases Involved in the Detoxification of Reactive Carbonyls in Plants*

  2010cites this paper
• Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation

  2010cites this paper
• Human carbonyl reductases.

  2010cites this paper
• Synthesis of 3-[(N-carboalkoxy)ethylamino]-indazole-dione derivatives and their biological activities on human liver carbonyl reductase.

  2010cites this paper
• New developments in anthracycline-induced cardiotoxicity.

  2009cites this paper
• Doxorubicin: the good, the bad and the ugly effect.

  2009cites this paper
• Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

  2009cites this paper
• Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3.

  2009cites this paper
• Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.

  2009cites this paper
• Identification of the Promoter of Human Carbonyl Reductase 3 (CBR3) and Impact of Common Promoter Polymorphisms on Hepatic CBR3 mRNA Expression

  2009cites this paper
• Role of transcriptional and translational gene regulation in the mechanism of doxorubicin cardiotoxicity.

  2009cites this paper
• Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart

  2009cites this paper
• The Effect of Sex and Background on Doxorubicin-Induced Cardiotoxicity in Carbonyl Reductase 1 +/- Mice: A Comparative Study

  2009cites this paper
• In vitro studies of allelic variation and function of aldo-keto reductases 1A1 and 1C2

  2009cites this paper
• RATIONAL DRUG DESIGN: AN INFORMATION DRIVEN APPROACH TO THE DESIGN OF AN ANTHRACYCLINE ANALOG

  2009cites this paper
• Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity

  2008cites this paper
• Cardiotoxicity of antitumor drugs.

  2008cites this paper
• Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

  2008cites this paper
• is a predominant doxorubicin reductase in the human liver

  2008cites this paper